ダウンロード数: 229

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
29_0009.pdf445.6 kBAdobe PDF見る/開く
タイトル: いわゆる細胞性免疫能賦活剤を投与した膀胱腫瘍症例の検討
その他のタイトル: Treatment of tumors of the urinary bladder with so-called immunopotentiators
著者: 辻村, 俊策  KAKEN_name
加藤, 次朗  KAKEN_name
上田, 公介  KAKEN_name
大田黒, 和生  KAKEN_name
著者名の別形: Tsujimura, Shunsaku
Kato, Jiro
Ueda, Kosuke
Ohtaguro, Kazuo
キーワード: Adjuvants, Immunologic/administration & dosage/therapeutic use
Aged
Antibiotics, Antineoplastic/therapeutic use
Biological Products/therapeutic use
Carcinoma, Squamous Cell/drug therapy/immunology
Carcinoma, Transitional Cell/drug therapy/immunology
Female
Humans
Levamisole/administration & dosage/therapeutic use
Male
Middle Aged
Phytohemagglutinins/immunology
Picibanil/administration & dosage/therapeutic use
Prognosis
Proteoglycans/administration & dosage/therapeutic use
Skin Tests
Urinary Bladder Neoplasms/drug therapy/immunology
発行日: Jan-1983
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 29
号: 1
開始ページ: 9
終了ページ: 15
抄録: Eighty-eight cases of urinary bladder tumor were treated in our Department from 1976 to 1978. The effect of so-called immunopotentiators (OK-432, Levamisole and PSK) was studied in 23 patients. The following results were obtained. Pretreatment intracutaneous response to PHA was significantly lower in the high stage and high grade group than in the low stage and low grade group (P less than 0.025). However, there was no correlation between the effect of immunotherapy and PHA skin reaction. Of the immunoglobulins, only IgM was significantly lower in the high grade group than in the low grade group (P less than 0.025). The one-year survival rate for the patients in the high stage group was higher receiving immunotherapy than those not treated. This suggests that immunotherapy may be useful for prolonging the survival time of patients with advanced bladder carcinoma.
URI: http://hdl.handle.net/2433/120107
PubMed ID: 6677093
出現コレクション:Vol.29 No.1

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。